Why it matters: The deal allows Neurimmune to raise substantial non-dilutive funding without issuing shares. Since the responsibility for cliramitug\u2019s costly late-stage development already sits with AstraZeneca, this money can directly be invested in the development of earlier-stage assets.<\/p>\n
By the numbers: Royalty Pharma will pay Neurimmune $125 million upfront and another $125 million in the first quarter of 2027. A further $175 million is tied to undisclosed clinical and regulatory milestones.<\/p>\n
In return, Royalty Pharma will receive a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune said it will retain a \u201csubstantial\u201d portion of its original royalty and milestone rights.<\/p>\n
Backstory: Neurimmune licensed cliramitug<\/a>\u00a0to AstraZeneca\u2019s rare disease unit Alexion in 2022.<\/p>\n That agreement included $30 million upfront, up to $730 million in potential milestones and royalties in the low-to-mid teens. AstraZeneca is responsible for further clinical development, manufacturing and commercialization.<\/p>\n Zoom in: Cliramitug is being tested in the Phase 3 DepleTTR-CM trial in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).<\/p>\n ATTR-CM is a progressive and often underdiagnosed heart disease caused by misfolded transthyretin proteins accumulating in the heart. The deposits thicken and stiffen the heart muscle, gradually reducing its ability to pump blood and leading to heart failure. The disease can be hereditary or develop with age, particularly in older men.<\/p>\n Most current treatments try to prevent further damage. TTR stabilisers such as tafamidis and acoramidis stop the protein from breaking apart and forming new deposits, while RNA-targeted therapies reduce its production in the liver.<\/p>\n Cliramitug takes a different approach: the antibody is designed to clear amyloid that has already accumulated in the heart. No amyloid-depleting treatment is currently approved for ATTR-CM.<\/p>\n Catch up quick: The distinction has become more relevant after AstraZeneca and Ionis\u2019 eplontersen recently failed<\/a> to significantly reduce cardiovascular deaths and clinical events when added to modern standard care in a Phase 3 trial.<\/p>\n The bigger picture: Royalty Pharma has become an increasingly influential source of capital as difficult public markets have pushed biotech companies to look beyond conventional fundraising.<\/p>\n The New York-based company agreed this year to provide up to $500 million to support Johnson & Johnson\u2019s development of an autoimmune antibody and up to $500 million for Teva\u2019s experimental vitiligo treatment. In both cases, Royalty Pharma\u2019s eventual return is linked to the programmes\u2019 commercial success.
\nIts portfolio generated $3.25 billion in receipts in 2025, up 16% from the previous year, illustrating the scale pharmaceutical royalty financing has reached.<\/p>\n